Status: Recruiting
Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas
The primary objective of this trial is to investigate whether the addition of 3 additional neo-adjuvant cycles of chemotherapy (doxorubicin based chemotherapy) to standard management according to the ISG-STS 10-01 study (3 cycles of neoadjuvant doxorubicin based chemotherapy + surgery +/- radiotherapy) improves the outcome of high-risk CINSARC patients with resectable soft-tissue sarcoma (STS). Primary endpoint is metastatic progression-free survival (M-PFS, after 3 years of follow-up).
Participants needed: 351
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Institut BergoniéUpdated: Oct 2, 2025Locations: 10
Eligibility criteria
Histologically confirmed soft-tissue sarcoma by the RRePS (Réseau de Référence e... [+11]
Soft-tissue sarcoma with the following histological subtypes: well-differentiate... [+10]